These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 15853576

  • 1. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
    Rudick RA, Sandrock A.
    Expert Rev Neurother; 2004 Jul; 4(4):571-80. PubMed ID: 15853576
    [Abstract] [Full Text] [Related]

  • 2. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
    Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators.
    N Engl J Med; 2006 Mar 02; 354(9):911-23. PubMed ID: 16510745
    [Abstract] [Full Text] [Related]

  • 3. Natalizumab for multiple sclerosis?
    Drug Ther Bull; 2008 Sep 02; 46(9):69-72. PubMed ID: 18784381
    [Abstract] [Full Text] [Related]

  • 4. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.
    Johnson KP.
    Neurologist; 2007 Jul 02; 13(4):182-7. PubMed ID: 17622909
    [Abstract] [Full Text] [Related]

  • 5. Natalizumab: targeting alpha4-integrins in multiple sclerosis.
    Engelhardt B, Kappos L.
    Neurodegener Dis; 2008 Jul 02; 5(1):16-22. PubMed ID: 18075270
    [Abstract] [Full Text] [Related]

  • 6. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.
    Rice GP, Hartung HP, Calabresi PA.
    Neurology; 2005 Apr 26; 64(8):1336-42. PubMed ID: 15851719
    [Abstract] [Full Text] [Related]

  • 7. The role of natalizumab in the treatment of multiple sclerosis.
    Coyle PK.
    Am J Manag Care; 2010 Jun 26; 16(6 Suppl):S164-70. PubMed ID: 20615052
    [Abstract] [Full Text] [Related]

  • 8. [Natalizumab in the treatment of multiple sclerosis].
    Horga A, Horga de la Parte JF.
    Rev Neurol; 2010 Jun 26; 45(5):293-303. PubMed ID: 17876741
    [Abstract] [Full Text] [Related]

  • 9. Multiple sclerosis and Natalizumab.
    Fiore D.
    Am J Ther; 2007 Jun 26; 14(6):555-60. PubMed ID: 18090880
    [Abstract] [Full Text] [Related]

  • 10. Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?
    Davenport RJ, Munday JR.
    Drug Discov Today; 2007 Jul 26; 12(13-14):569-76. PubMed ID: 17631252
    [Abstract] [Full Text] [Related]

  • 11. Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody.
    Drugs R D; 2004 Jul 26; 5(2):102-7. PubMed ID: 15293871
    [Abstract] [Full Text] [Related]

  • 12. Health-related quality of life in multiple sclerosis: effects of natalizumab.
    Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, Galetta SL, Giovannoni G, Havrdova E, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, AFFIRM and SENTINEL Investigators.
    Ann Neurol; 2007 Oct 26; 62(4):335-46. PubMed ID: 17696126
    [Abstract] [Full Text] [Related]

  • 13. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab.
    Steinman L.
    Nat Rev Drug Discov; 2005 Jun 26; 4(6):510-8. PubMed ID: 15931259
    [Abstract] [Full Text] [Related]

  • 14. Natalizumab: new drug. Multiple sclerosis: risky market approval.
    Prescrire Int; 2008 Feb 26; 17(93):7-10. PubMed ID: 18354844
    [Abstract] [Full Text] [Related]

  • 15. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
    Stüve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Jerome KR, Cook L, Grand'Maison F, Hemmer B, Monson NL, Racke MK.
    Arch Neurol; 2006 Oct 26; 63(10):1383-7. PubMed ID: 17030653
    [Abstract] [Full Text] [Related]

  • 16. Natalizumab in the treatment of patients with multiple sclerosis: first experience.
    Mareckova H, Havrdova E, Krasulova E, Vankova Z, Koberová M, Sterzl I.
    Ann N Y Acad Sci; 2007 Sep 26; 1110():465-73. PubMed ID: 17911462
    [Abstract] [Full Text] [Related]

  • 17. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
    Wipfler P, Oppermann K, Pilz G, Afazel S, Haschke-Becher E, Harrer A, Huemer M, Kunz A, Golaszewski S, Staffen W, Ladurner G, Kraus J.
    Mult Scler; 2011 Jan 26; 17(1):16-23. PubMed ID: 20937631
    [Abstract] [Full Text] [Related]

  • 18. Natalizumab for multiple sclerosis.
    Ransohoff RM.
    N Engl J Med; 2007 Jun 21; 356(25):2622-9. PubMed ID: 17582072
    [No Abstract] [Full Text] [Related]

  • 19. Natalizumab. Elan/Biogen.
    Elices MJ.
    Curr Opin Investig Drugs; 2003 Nov 21; 4(11):1354-62. PubMed ID: 14758775
    [Abstract] [Full Text] [Related]

  • 20. Natalizumab for the treatment of multiple sclerosis and Crohn's disease.
    Keeley KA, Rivey MP, Allington DR.
    Ann Pharmacother; 2005 Nov 21; 39(11):1833-43. PubMed ID: 16219898
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.